Targeted Drugs for Waldenstrom Macroglobulinemia

As researchers have learned more about the changes inside cells that cause cancer, they have developed newer drugs that target these changes. They are often referred to as targeted therapy. These drugs work differently from standard chemotherapy (chemo) drugs. They sometimes work when chemo drugs don’t, and they often have different (and less severe) side effects.

Proteasome inhibitors

These drugs stop enzyme complexes (proteasomes) inside cells from breaking down proteins that normally help keep cell division under control.

Bortezomib (Velcade®) and carfilzomib (Kyprolis®) are often used to treat multiple myeloma. They have also been found to be helpful in some cases of WM. These drugs are given as an infusion into a vein (IV); bortezomib can also be given as an injection under the skin (sub-q).

Although these drugs work slightly differently from most chemo drugs, they can still cause many of the same types of side effects, including low blood counts, nausea, and loss of appetite. They can also damage nerves, causing pain in the feet and legs (peripheral neuropathy). The nerve damage usually gets better after the drug is stopped, but it might not go away completely.

mTOR inhibitors

These drugs block a cell protein known as mTOR, which normally helps cells grow and divide into new cells.

Everolimus (Afinitor®) is used more often to treat some other types of cancer, but it has also been shown to be useful in treating WM after other treatments have been tried. This drug is taken daily as a pill. Common side effects include fatigue (tiredness), mouth pain, rash, diarrhea, and infections.

Other mTOR inhibitors, such as temsirolimus (Torisel®), are now being studied to see if they can help treat WM as well.

Bruton tyrosine kinase (BTK) inhibitors

Ibrutinib (Imbruvica®) blocks a protein called Bruton tyrosine kinase (BTK) inside lymphoma cells, which normally helps the cells grow and survive. This drug can be used alone to treat WM, or in combination with rituximab . Ibrutinib is taken by mouth, once a day. Common side effects include diarrhea or constipation, nausea and vomiting, fatigue, swelling, decreased appetite, and low blood counts.

Other drugs that block BTK or other kinases in lymphoma cells are also being studied for use against WM (see What’s New in Waldenstrom Macroglobulinemia Research ?).

The American Cancer Society medical and editorial content team

Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as journalists, editors, and translators with extensive experience in medical writing.

Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31:88–94.

Buske C, Leblond V, Dimopoulos M, et al. Waldenstrom’s macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24 Suppl 6:vi155–159.

Dimopoulos MA et al. Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia. N Engl J Med. 2018; 378:2399-2410. 

Gertz MA. Waldenström macroglobulinemia: 2017 update on diagnosis, risk stratification, and management. Am J Hematol. 2017;92:209-217.

Ghobrial IM, Witzig TE, Gertz M, et al. Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia. Am J Hematol. 2014;89:237–242.

National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Waldenstrom’s macroglobulinemia/Lymphoplasmacytic lymphoma. V.1.2018. Accessed at on June 21, 2018.

Rajkumar SV, Dispenzieri A. Chapter 104: Multiple myeloma and related disorders. In: Niederhuber JE, Armitage JO, Dorshow JH, Kastan MB, Tepper JE, eds. Abeloff’s Clinical Oncology. 5th ed. Philadelphia, Pa. Elsevier: 2014.

Last Revised: July 19, 2018

American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.